Abstract:
본 발명은 이종 항원 단백질을 발현하며, 보르데텔라 브론키셉티카의 aroA 유전자가 제거된 약독화된 보르데텔라 브론키셉티카(Bordetella bronchiseptica) 균주, 그를 포함하는 면역원성 조성물, 그를 이용한 포유동물의 이종 항원 원인균 감염증 및/또는 보르데텔라 브론키셉티카 감염증을 치료 또는 예방하는 방법 및 이종 항원 단백질을 발현하는 약독화된 보르데텔라 브론키셉티카 균주의 제조 방법을 제공한다. 약독화 보르데텔라 브론키셉티카, aroA 유전자, 면역원성 조성물, 상동 재조합, 이종단백질 항원 발현
Abstract:
A live attenuated Bordetella bronchiseptica strain for revealing a heterogenetic antigen protein is provided to have immunogenicity, to weaken toxicity, to reveal the heterogenetic antigen and to be used as a vaccine for prevention and a strain for treatment to a PCV2. A live attenuated Bordetella bronchiseptica strain reveals a heterogenetic antigen protein and removes an aroA gene of the Bordetella bronchiseptica. The heterogenetic antigen protein is a dimorphism porcine circovirus(PCV2) capsid protein having an amino acid sequence of a sequence number 1. The aroA gene has a base sequence of a sequence number 2. A deposit number of the strain is KCCM-10855P.
Abstract:
An attenuated Bordetella bronchiseptica(BBS) strain is provided to exhibit immunogenicity and show attenuated toxicity, thereby being be used as a live vaccine. An immunogenic composition comprising the same is provided to induce production of an antibody against BBS toxin in case of being administered into mammal. An attenuated BBS strain is characterized in that an aroA gene is deleted therefrom through homologous recombination and is deposited as a deposition no. KCCM-10840P. An immunogenic composition for treating or preventing BBS infection of mammal comprises the attenuated BBS strain and a pharmaceutically acceptable carrier or an adjuvant. Further, the aroA gene has SEQ ID : NO. 1.
Abstract translation:提供减毒支气管炎博德特氏菌(BBS)菌株以表现出免疫原性并显示减毒毒性,从而用作活疫苗。 提供包含其的免疫原性组合物以在施用于哺乳动物的情况下诱导产生抗BBS毒素的抗体。 减毒BBS菌株的特征在于通过同源重组将aroA基因从其中缺失,并作为沉积物沉积。 KCCM-10840P。 用于治疗或预防哺乳动物BBS感染的免疫原性组合物包含减毒的BBS菌株和药学上可接受的载体或佐剂。 此外,aroA基因具有SEQ ID NO: 1。